LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

40.29 1.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

39.5

Max

40.58

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Peļņas marža	-1,582.642
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+2.32% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.8B 5.9B
Iepriekšējā atvēršanas cena	38.75
Iepriekšējā slēgšanas cena	40.29

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. nov. 17:44 UTC

Peļņas

Galvenie tirgus virzītāji

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

2025. g. 27. nov. 00:00 UTC

Tirgus saruna

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

2025. g. 26. nov. 23:47 UTC

Tirgus saruna

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

2025. g. 26. nov. 23:28 UTC

Tirgus saruna

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

2025. g. 26. nov. 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. nov. 23:21 UTC

Tirgus saruna

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

2025. g. 26. nov. 23:02 UTC

Tirgus saruna

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

2025. g. 26. nov. 21:38 UTC

Peļņas

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

2025. g. 26. nov. 21:25 UTC

Peļņas

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

2025. g. 26. nov. 21:17 UTC

Iegādes, apvienošanās, pārņemšana

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

2025. g. 26. nov. 21:16 UTC

Peļņas

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

2025. g. 26. nov. 21:09 UTC

Peļņas

Roblox Isn't Playing Games. Why the Stock Could -2-

2025. g. 26. nov. 21:09 UTC

Peļņas

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

2025. g. 26. nov. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

2025. g. 26. nov. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

2025. g. 26. nov. 20:15 UTC

Peļņas

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

2025. g. 26. nov. 20:08 UTC

Tirgus saruna

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2025. g. 26. nov. 20:06 UTC

Tirgus saruna

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

2025. g. 26. nov. 19:30 UTC

Peļņas

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

2025. g. 26. nov. 19:21 UTC

Iegādes, apvienošanās, pārņemšana

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

2025. g. 26. nov. 18:43 UTC

Tirgus saruna

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

2025. g. 26. nov. 18:41 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

2025. g. 26. nov. 18:19 UTC

Peļņas

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

2025. g. 26. nov. 17:51 UTC

Peļņas

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

2025. g. 26. nov. 17:50 UTC

Peļņas

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

2025. g. 26. nov. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 26. nov. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 26. nov. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 26. nov. 17:16 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

2025. g. 26. nov. 17:16 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

2.32% augšup

Prognoze 12 mēnešiem

Vidējais 40.64 USD 2.32%

Augstākais 65 USD

Zemākais 20 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.